THYROCARE
Healthcare ServicesThyrocare Technologies Limited
Thyrocare Technologies Limited (Thyrocare) is a chain of diagnostic centers in India that provides services for preventative healthcare and was founded in 1996. The company has a network of over 4,000 service providers and operates across more than 2,000 cities in India.
Thyrocare has grown significantly over the years, and has become one of the largest diagnostic services providers in India, providing a wide range of pathology and radiology services. It went public in 2016.
The company's financial performance has been strong, with revenue growing consistently in recent years. The latest available revenue figures for the company are for the year ended March 31, 2021, where the company reported a revenue of INR 883.6 crore. The profit figure for the same year was INR 97.3 crore.
The major product mix for Thyrocare by revenue is preventative health check-up services. The company's services also include various pathology and radiology tests.
The major growth driver for Thyrocare in the future is expected to be the increasing demand for preventive health check-up services in India due to rising awareness about health and wellness. The growing Indian middle class and their increasing disposable incomes are also expected to drive growth.
Thyrocare operates in a highly competitive industry, with many players offering similar services. Some of the major competitors of Thyrocare include Dr. Lal PathLabs, Metropolis Healthcare, and SRL Limited.
- Trades at a P/E of 45.2, with a return on equity (ROE) of 13.1%.
- THYROCARE is trading above 4 of 5 of its key moving averages (10/20/50/100/200-DMA) — a bullish technical setup.
- Year-to-date it is up 24.2%, and down 63.84% over the past year.
- At ₹564.25 it sits about 17% of the way up its 52-week range (₹342.55–₹1,610.00).
- Offers a dividend yield of 2.77%.
- Market capitalisation stands at ₹2,993 Cr.
Shareholding data syncs daily.
| Year | Revenue | Net Profit | EPS | NPM |
|---|---|---|---|---|
| Mar 2023 | ₹486 Cr | ₹57 Cr | ₹10.76 | 11.73% |
| Mar 2022 | ₹562 Cr | ₹152 Cr | ₹28.74 | 27.05% |
| Mar 2021 | ₹495 Cr | ₹113 Cr | ₹21.40 | 22.83% |
| Mar 2021 | ₹495 Cr | ₹113 Cr | ₹21.40 | 22.83% |
| Mar 2020 | ₹433 Cr | ₹88 Cr | ₹16.73 | 20.32% |
| Mar 2020 | ₹433 Cr | ₹88 Cr | ₹16.73 | 20.32% |
| Mar 2019 | ₹403 Cr | ₹85 Cr | ₹16.13 | 21.09% |
| Mar 2019 | ₹403 Cr | ₹85 Cr | ₹16.13 | 21.09% |
| Mar 2018 | ₹356 Cr | ₹93 Cr | ₹17.36 | 26.12% |
| Mar 2017 | ₹304 Cr | ₹43 Cr | ₹7.98 | 14.14% |
| Mar 2016 | ₹241 Cr | ₹52 Cr | ₹9.64 | 21.58% |
| Mar 2015 | ₹183 Cr | ₹45 Cr | ₹8.95 | 24.59% |
| Company | P/E | Book Value | Sales Growth |
|---|---|---|---|
| VIMTALABS Vimta Labs Ltd. | 17.4 | ₹76.05 | 15.5% |
| SASTASUNDR Sastasundar Ventures Ltd | 2,574 | ₹85.89 | 13.37% |
| LALPATHLAB Dr. Lal PathLabs Ltd | 60.36 | ₹124.95 | 15.03% |
| ASTERDM Aster DM Healthcare Ltd | 168.12 | ₹58.79 | 46.52% |
| METROPOLIS Metropolis Healthcare Ltd | 71.25 | ₹92.41 | 18.5% |
| VIJAYA Vijaya Diagnostic Centre Ltd | 70.6 | ₹41.30 | — |
| Date | Client | Type | Qty | Price |
|---|---|---|---|---|
| 25 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | SALE | 1,23,725 | ₹2,112.90 |
| 25 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | PURCHASE | 1,23,725 | ₹2,112.90 |
| 25 Oct 2022 | ISHARES INDIA SC MAURITIUS COMPANY | SALE | 16,709 | ₹2,112.90 |
| 25 Oct 2022 | ISHARES MSCI INDIA SMALL-CAP ETF | PURCHASE | 16,709 | ₹2,112.90 |
| 17 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | SALE | 1,23,604 | ₹2,026.25 |
| 17 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | PURCHASE | 1,23,604 | ₹2,026.25 |
| 17 Oct 2022 | ISHARES INDIA SC MAURITIUS COMPANY | SALE | 16,692 | ₹2,026.25 |
| 17 Oct 2022 | ISHARES MSCI INDIA SMALL-CAP ETF | PURCHASE | 16,692 | ₹2,026.25 |
| 19 Sept 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | SALE | 41,105 | ₹2,561.10 |
| 19 Sept 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | PURCHASE | 41,105 | ₹2,561.10 |
| 19 Sept 2022 | ISHARES INDIA SC MAURITIUS COMPANY | SALE | 5,507 | ₹2,561.10 |
| 19 Sept 2022 | ISHARES MSCI INDIA SMALL-CAP ETF | PURCHASE | 5,507 | ₹2,561.10 |
Fundamentals, financials & technicals sourced from niftytrader.in, cached and refreshed periodically.